Novo Nordisk has formed a four-weeks-tight pattern ahead of fourth-quarter results on Wednesday.

The post Leader In Weight-Loss Drugs Nears Buy Point After 53% Gain And Accelerating Growth; Earnings Due This Week appeared first on Investor’s Business Daily.